BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

AstraZeneca's FluMist is one step closer to making its return next flu season.

After two refusals from Sanofi to provide a refund for the Dengvaxia program, officials in the Philippines say they are getting ready to sue.

Flu vaccine specialist Seqirus grew sales 26% in the six months leading up to Dec. 31, driven by a portfolio shift.

Vaccine protection against H3N2 viruses—the predominant strain that tends to cause more severe illness—was only 25% this year.

Here is some other vaccine news of note for the week.

While only in the very early stages of its important Shingrix launch, GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.